生技藥品市場規模、佔有率、成長分析，按產品、按來源、按應用、按疾病、按製造業、按地區 - 行業預測，2024-2031

2022年生技藥品市場規模將達到4,620億美元，預測期（2024-2031年）複合年成長率為10.40%，從2023年的5100.5億美元成長到2031年的11255.5億美元，預計將成長至1000萬美元。

生技藥品市場正在幫助為許多疾病提供創新和有效的治療方法，透過有針對性的個人化解決方案徹底改變治療方法。這些複雜的藥物透過重組 DNA 技術等先進的生物技術製程生產，對於治療癌症、自體免疫疾病和感染疾病等慢性疾病至關重要。市場成長背後的驅動力是此類疾病在全球範圍內的日益流行，創造了對生技藥品的巨大需求。然而，高成本、製造複雜以及需要特殊儲存和運輸條件的溫度和環境敏感性等挑戰使供應鏈變得複雜。在利用個人化醫療和新興技術的進步的同時解決這些問題對於市場的未來發展至關重要。

目錄

介紹

• 這項研究的目的
• 定義
• 市場範圍

調查方法

• 資訊採購
• 次要/一級資訊來源
• 市場規模預測
• 市場假設與限制

執行摘要

• 市場概況展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場動態
  • 促進因素
  • 機會
  • 抑制因素
  • 任務
• 波特的分析

關鍵生技藥品市場洞察

• 技術分析
• 市場生態系統
• 專利分析
• Start-Ups分析
• 監管環境
• 創新矩陣
• 主要投資分析
• 關鍵成功因素
• 競爭程度

生技藥品市場：依產品

• 市場概況
• 單株抗體
• 疫苗
• 重組生長因子
• 重組蛋白
• 重組激素
• 重組酵素
• 合成免疫調節劑
• 反義/RNAi
• 治療藥物
• 其他

生技藥品市場：依來源分類

• 市場概況
• 微生物
• 哺乳動物的
• 其他

生技藥品市場：依應用分類

• 市場概況
• 診斷
• 治療性的
• 蛋白質精製
• 其他

生技藥品市場：依疾病分類

• 腫瘤學
• 心血管
• 免疫疾病
• 感染疾病
• 代謝性疾病

生技藥品市場：依製造業分類

• 市場概況
• 外包
• 公司內部

生技藥品市場規模：依地區分類

• 市場概況
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲 (MEA)
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲地區

競爭格局

• 前5名企業對比
• 主要企業市場定位（2023年）
• 主要市場參與者所採取的策略
• 近期市集活動
• 主要企業市場佔有率（2023年）

主要企業簡介

• Roche（Switzerland）
• Johnson & Johnson（US）
• AbbVie（US）
• Amgen（US）
• Novartis（Switzerland）
• Pfizer（US）
• Merck & Co.（US）
• AstraZeneca（UK）
• Bristol Myers Squibb（US）
• Sanofi（France）
• Eli Lilly and Company（US）
• Gilead Sciences（US）
• Biogen（US）
• Samsung Biologics（South Korea）
• Novo Nordisk（Denmark）
• Takeda Pharmaceutical Company（Japan）
• Bayer（Germany）
• GlaxoSmithKline（UK）
• Boehringer Ingelheim（Germany）
• Vertex Pharmaceuticals（US）

Biologics Market size was valued at USD 462 Billion in 2022 and is poised to grow from USD 510.05 Billion in 2023 to USD 1125.55 Billion by 2031, at a CAGR of 10.40% during the forecast period (2024-2031).

The biologics market is instrumental in delivering innovative and effective therapies for numerous diseases, significantly transforming treatment approaches with targeted and personalized solutions. These complex drugs, produced through advanced biotechnological processes such as recombinant DNA technology, are essential in managing chronic conditions like cancer, autoimmune disorders, and infectious diseases. The market's growth is driven by the increasing prevalence of such diseases worldwide, creating substantial demand for biologics. However, challenges like high costs, intricate manufacturing, and the need for specialized storage and transportation conditions due to their sensitivity to temperature and environment, complicate the supply chain. Addressing these issues while leveraging advancements in personalized medicine and emerging technologies will be crucial for the market's future development.

Top-down and bottom-up approaches were used to estimate and validate the size of the Biologics Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Biologics Market Segmental Analysis

The biologics market is segmented by product, source, application, disease, manufacturing, and region. By product, the market can be segmented into Monoclonal Antibodies, Vaccines, Recombinant Growth Factors, Recombinant Proteins, Recombinant Hormones, Recombinant Enzymes, Synthetic Immunomodulators, Antisense & RNAi, Therapeutics, and Others. By source, the market is segmented into microbial, mammalian, and others. By application, the market is segmented into Diagnostic, Therapeutic, Protein Purification, and Others. By disease, the market is segmented into oncology, cardiovascular, immunological diseases, infectious diseases, and metabolic diseases. By manufacturing, the market is segmented into outsourced, and in-house. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Biologics Market

The increasing incidence of chronic diseases like cancer, autoimmune disorders, and diabetes is significantly boosting the biologics market. Biologics provide targeted, personalized treatments, enhancing patient outcomes. In 2022, the FDA approved multiple biologics for cancer treatment, such as Keytruda (pembrolizumab) and Opdivo (nivolumab), underscoring their vital role in modern medicine. These approvals highlight the potential of biologics to revolutionize chronic disease management by offering more precise and effective therapeutic options, thus improving the quality of life for many patients suffering from these severe health conditions.

Restraints in the Biologics Market

The substantial expenses linked to developing, manufacturing, and distributing biologics pose a considerable challenge to the expansion of the market. The intricate manufacturing procedures, rigorous regulatory standards, and costly research and development endeavours collectively drive up the prices of biological medications. As a result, accessibility and affordability are constrained, especially in less affluent regions. The intricate nature of biologic drug production, coupled with stringent regulatory demands and the substantial costs associated with research and development, results in higher prices that can hinder access to these medicines, particularly in developing areas where financial resources are limited.

Market Trends of the Biologics Market

Personalized medicine, or precision medicine, is increasingly prominent in the biologics sector, focusing on customizing treatments according to patients' unique genetic, environmental, and lifestyle characteristics. This approach leverages advancements in genomics and molecular diagnostics to pinpoint specific biomarkers and genetic mutations, which in turn drives the creation of targeted biologic therapies. Drugs such as Keytruda and Herceptin (trastuzumab), designed to target precise genetic mutations in cancer patients, highlight the shift towards personalized medicine. This trend signifies a departure from one-size-fits-all approaches to healthcare, promising more effective and tailored treatments that enhance patient outcomes through a deeper understanding of individual biological nuances.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Biologics Market Insights

• Technology Analysis
• Ecosystem of the Market
• Patent Analysis
• Start-up Analysis
• Regulatory Landscape
• Innovation Matrix
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

Biologics Market by Product

• Market Overview
• Monoclonal Antibodies
• Vaccines
• Recombinant Growth Factors
• Recombinant Proteins
• Recombinant Hormones
• Recombinant Enzymes
• Synthetic Immunomodulators
• Antisense & RNAi
• Therapeutics
• Others

Biologics Market by Source

• Market Overview
• Microbial
• Mammalian
• Others

Biologics Market by Application

• Market Overview
• Diagnostic
• Therapeutic
• Protein Purification
• Others

Biologics Market by Disease

• Oncology
• Cardiovascular
• Immunological Diseases
• Infectious Diseases
• Metabolic Diseases

Biologics Market by Manufacturing

• Market Overview
• Outsourced
• In-house

Biologics Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Samsung Biologics (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novo Nordisk (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vertex Pharmaceuticals (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments